Skip to main content
LM

Legacy Medical Consultants

Legacy Medical Consultants specializes in the development and management of amniotic membrane allografts for wound care, utilizing placental tissue to promote healing and reduce complications. Their products have demonstrated a 28% reduction in the risk of major amputation and a 20% decrease in 30-day mortality rates for patients with chronic wounds.

Founded 202021500+ followers
Updated 4 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Chronic wounds pose a significant challenge in healthcare, often leading to complications such as infections, amputations, and increased mortality rates. Traditional wound care methods may be insufficient for certain patients, particularly those with underlying conditions that impair healing.

Solution

Legacy Medical Consultants provides advanced wound care solutions using amniotic membrane allografts derived from placental tissue. These allografts are designed to promote tissue regeneration, reduce inflammation, and accelerate the healing process in chronic wounds. Clinical studies have demonstrated that the application of Legacy Medical's allografts is associated with a significant reduction in the risk of major amputation and a decrease in 30-day mortality rates for patients with chronic wounds. The company offers a range of allograft products, including Zenith™, Impax™, Orion™, Complete ACA™, SurGraft FT™, and Reeva FT™, each tailored to specific wound types and patient needs.

Target Audience

The primary target audience includes healthcare providers and patients seeking advanced wound care solutions for chronic wounds, such as diabetic ulcers, venous leg ulcers, and pressure ulcers.

Features

  • Amniotic membrane allografts derived from placental tissue
  • Products include Amnion-only allografts (Zenith™, Impax™, Orion™) and Amnion + Chorion allografts (Complete ACA™, SurGraft FT™, Reeva FT™)
  • Manufactured in a state-of-the-art US facility compliant with FDA regulations
  • Designed to promote tissue regeneration and reduce inflammation
  • Supported by clinical evidence demonstrating reduced amputation risk and mortality rates
This profile is AI-generated and may contain inaccuracies.